Compugen Ltd (id:6927 CGEN)
1.60 USD
Opening hours: 09:30 - 16:00 (Eastern Standard Time: 12/25/2024 11:03:42 AM)
Exchange open, closes in 4 hours 56 minutes
About Compugen Ltd
Market Capitalization 136.54M
Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company's immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; COM902, a therapeutic antibody targeting TIGIT, which is in Phase I monotherapy clinical study in patients with advanced malignancies through sequential dose escalations; Bapotulimab, a therapeutic antibody targeting ILDR2 that is in Phase I clinical study in patients with naïve head and neck squamous cell carcinoma; and Rilvegostomig, a novel anti-TIGIT/PD-1 bispecific antibody, which is in Phase II clinical study in patients with advanced or metastatic non-small cell lung cancer. Its therapeutic pipeline also includes early-stage immuno-oncology programs focused to address various mechanisms of immune resistance; and COM503, high affinity antibody, which blocks the interaction between IL-18 binding protein and IL-18. The company has collaboration agreement with Bayer Pharma AG for the research, development, and commercialization of antibody-based therapeutics against the company's immune checkpoint regulators; Bristol-Myers Squibb to evaluate the safety and tolerability of COM701 in combination with Bristol-Myers Squibb's PD-1 immune checkpoint inhibitor Opdivo in patients with advanced solid tumors; and Johns Hopkins School of Medicine to evaluate novel T cell and myeloid checkpoint targets. It has license agreement with AstraZeneca for the development of bi-specific and multi-specific immuno-oncology antibody products; and research collaboration with Johns Hopkins University for myeloid. Compugen Ltd. was incorporated in 1993 and is headquartered in Holon, Israel.
Headquarters (address) |
Azrieli Center Holon 5885849 Israel |
Phone | 972 3 765 8585 |
Website | https://cgen.com |
Employees | 68 |
Sector | Healthcare |
Industry | Biotechnology |
Ticker | CGEN |
Exchange | NASDAQ Stock Exchange |
Currency | USD |
52 week range | 1.35 - 3.03 |
Market Capitalization | 136.54M |
P/E trailing | 50.83 |
P/E forward | -13.86 |
Price/Sale | 3.20 |
Price/Book | 2.07 |
Beta | 2.65 |
EPS | 5.00 |
EPS Israel (ID:92, base:52) | 3.00 |